Stephanie SOLIER

I have over 16 years of experience in cancer research. After obtaining my pharmacy degree (Toulouse, France), I completed my residency in the research field. I was interested in the biology of the cell and its deregulation in diseases, especially when leading to malignancy. My PhD studies were dedicated to understanding the role of topoisomerases in alternative splicing, with a focus on caspase-2 gene as a target (Inserm U517, Dijon, France - Dr Corcos). My post-doctoral fellowship focused on the crosstalk between DNA damage and cell death (Inserm-NIH contract, Bethesda, US - Dr Pommier) which led to the discovery of a novel entity, "the γ-H2AX apoptotic ring". Then, I consolidated my expertise in Cancerology at Gustave Roussy Institute (Inserm U1170, Villejuif, France - Pr Solary), where I depicted a novel pathway and found that caspase inhibition could be a clinically efficient strategy to modulate macrophage polarization in damaged tissues. In 2019, my interest in the immune system during malignancy and tissue damage led me to join the Curie Institute (INSERM U1339, Paris, France - Dr Rodriguez). I am currently working on the role of metals in tumor development, and recently I reported with colleagues that mitochondrial copper controls cell plasticity and drives inflammation.